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Event adjudication is considered to be a cornerstone of best practice for clinical trials. Scrutiny 3 
of trial endpoints by an independent committee blinded to the trial intervention, provides a 4 
robust platform and confidence for the primary trial findings. However, this apparent “gold-5 
standard” is a complex process where data can be missing or incomplete, and decisions are 6 
rigidly protocolised whilst interpretation is subjective. Moreover, there is conflicting evidence 7 
in the literature regarding its ability to reduce misclassification of events. Although individual 8 
studies demonstrate how adjudication can add credibility and ensure that data are of 9 
sufficient quality, systematic reviews suggest the overall effect size estimates are unaltered. 10 
Indeed, the perception that endpoint decisions made by an adjudication committee are 11 
superior to that of the site investigator has never been validated. In view of the substantial 12 
financial and personnel cost that is associated with event adjudication, careful consideration 13 
should be made surrounding the methodology chosen and the benefits gained. Alternative 14 
strategies, including the use of routinely collected data, are increasingly being used to deliver 15 
randomised controlled trials more efficiently and effectively. This may ultimately be more 16 
reflective of real-world practice and indicative of healthcare impact.  17 
  18 
 3 
In pivotal clinical effectiveness trials, the primary endpoint needs to be precisely defined and 19 
quantified because any misclassification may introduce noise and possible bias, potentially 20 
leading to incorrect trial conclusions. This is commonly addressed by having an independent 21 
clinical endpoint adjudication committee where all relevant clinical information is provided 22 
and a panel of clinical experts categorises the primary endpoint, blind to treatment allocation. 23 
This has been established as a basic cornerstone of modern robust trial methodology. 24 
However, does this apparently rigorous approach truly deliver more robust clinical findings?  25 
 26 
The underlying premise is that adjudication will be more accurate, reduce noise and limit any 27 
misclassification by the site investigator, with any residual errors being consistently 28 
distributed across the treatment groups.  However, adjudication may neither improve 29 
classification nor be an accurate reflection of ‘true events’.1 The site investigator has the 30 
advantage of full clinical context and documentation as well as an intimate understanding of 31 
the clinical situation at the site.  An external clinical endpoint committee will be remote from 32 
the event and has to rely on, at times, incomplete data, poor source documentation and a 33 
formulaic protocol-driven definition of the endpoint. Site investigators can be variable in their 34 
response to requests for source data to verify events. This can be a major problem for 35 
international trials. Inevitably, differences in event classification will arise, but who is the 36 
more likely to be correct? As far as we are aware, there has yet to be a formal comparison of 37 
local assessment with central adjudication where the absolute truth is definitively known. 38 
Generally, if not exclusively, trials assume that central adjudication is more accurate than 39 
local adjudication, and so presents the central findings as the primary analysis. But is this 40 
always justified or true?    41 
 42 
 4 
Methodology of Clinical Endpoint Committees 43 
The effective ability to apply a standard definition decreases with increasing complexity of 44 
the clinical case and endpoint definition (Panel: Clinical Case Example 1). As Plesk and 45 
colleagues highlight, although definitions allow us to ‘reduce and resolve’ clinical cases into 46 
neat boxes, ‘unpredictability and paradoxes are ever present’ and some things will always 47 
remain unclear.2 In such situations, results are subjective. As such, the methodology behind 48 
event adjudication warrants close inspection. What clinical expertise or training is required in 49 
order to sit on an adjudication panel? If central adjudicators are used, should they adjudicate 50 
every suspected outcome or only selected outcomes? Should adjudications be conducted 51 
independently or in a consensus committee? Kahan and colleagues in their detailed review of 52 
the statistical properties of various adjudication methods, felt that no single approach fits all.3  53 
 54 
In most cases, adjudication panels rely on information from site investigators and this can be 55 
insensitive, conservative and restricted to deciding whether events the site has deemed 56 
worthy of reporting meet the endpoint. Although attempts can be made to screen for 57 
unreported events (Appendix: Clinical Trial Example 1),4,5 they are costly and resource 58 
intensive. These problems not only apply to disease diagnoses, but also to death. Many 59 
countries have incomplete death certification and the cause of death can be very difficult to 60 
determine. Indeed, it can be based on the testimony of witnesses, colleagues or estranged 61 
family members (Panel: Clinical Case Example 2). In a meta-analysis of 9 clinical trials with a 62 
total of 9,259 centrally adjudicated deaths, approximately 16% had an undetermined cause.6 63 
There are also cultural and religious issues in attributing cause of death. For example, the 64 
acceptability of recording suicide varies considerable across the globe.7 Clinical endpoint 65 
 5 
adjudication committees often resort to classifying a number of events by consensus rather 66 
than unanimously, underlining that subjectivity and uncertainty remains.  67 
 68 
What is the variability and cost of Clinical Endpoint Adjudication? 69 
There can be marked variability in the attribution of a clinical endpoint with site investigators 70 
and clinical endpoint adjudication committees often disagreeing, especially with complex or 71 
subjective endpoints. Which opinion is most valid? One could argue that the clinical endpoint 72 
committees select only definitive cases excluding the more questionable ones. However, the 73 
evidence for this is lacking. Hallen and colleagues found that in a blinded “re-adjudication” of 74 
10 of the most challenging cases and 10 randomly selected consistently adjudicated cases, 75 
the re-adjudicated outcomes changed in 11 cases: a discordance rate of 55%.8 Does this mean 76 
the trial conclusions should have been reconsidered?  77 
 78 
Adjudication is expensive.9 Data needs to be collated, redacted to remove participant or 79 
treatment identifiable information, and sent to the trial coordinating centre. This is time 80 
consuming and often an iterative process requiring repeated communications between the 81 
sponsor, the site investigator and the clinical endpoint adjudication committee (Appendix: 82 
Clinical Trial Example 2).10 The overall financial and personnel costs should not be 83 
underestimated. For international trials, this can additionally involve addressing issues of 84 
transmitting data across regulatory borders.  85 
 86 
Is adjudication better than site reporting when determining endpoints? 87 
Advocates for adjudication point to evidence that where there is disagreement between 88 
clinical event committees and site investigators, the participant’s prognosis is often 89 
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worse.11,12 This highlights that disagreements are almost always over endpoint definition in 90 
complex and high-risk cases. Despite this, effect size estimates often remain unchanged 91 
regardless of using adjudicated or site reported endpoints (Appendix: Clinical Trial Examples 92 
1 and 2). These findings are not limited to trials where events are defined by biomarkers, such 93 
as troponin concentrations and myocardial infarction, but also where endpoints can be clearly 94 
defined, such as studies of patients with stroke.23,24 Moreover, there are examples where site 95 
investigator reporting demonstrates greater effect sizes of more clinically relevant events 96 
than clinical endpoint adjudication which identified milder subclinical events (Appendix: 97 
Clinical Trial Example 3).13  98 
 99 
Are these one-off examples? Systematic reviews have assessed the impact of clinical endpoint 100 
adjudication committee decisions regarding endpoint classification and compared them to 101 
those ascribed by site investigators. A meta-analysis of 10 trials by Pogue and colleagues14 102 
concluded that after reviewing over 95,000 patients and 9,000 events, no changes were 103 
detected in the treatment effect due to adjudication. A subsequent COCHRANE review of 47 104 
randomised controlled trials found that treatment effect estimates did not differ, although 105 
there were differences where site investigators were unblinded to the treatment allocation.15 106 
It concluded that independent adjudication may be important, but raised doubts about the 107 
appropriate use of adjudication in double blind randomised controlled trials.  108 
 109 
A common perception is that adjudication leads to confidence in the clinical trial findings. 110 
However, there are examples where this is not the case (Appendix: Clinical Trial Example 111 
4).16–20 Safety endpoints are also often seen as necessary to adjudicate but there are 112 
importance differences in the nuance of reporting and analysis here. Efficacy is usually 113 
 7 
evaluating a single central outcome, safety analyses are looking for non-specific indications 114 
of harm across a spectrum of multiple outcomes. This added complexity may lead to 115 
important safety issues being misattributed by the clinical endpoint adjudication committee 116 
(Appendix: Clinical Trial Example 5).21,22  117 
 118 
What are the alternatives? 119 
Many countries around the world have unified health records data, especially where there is 120 
advanced national public healthcare provision. Some observers have been critical of the 121 
absence of endpoint adjudication in trials using these data and point to inaccuracies of 122 
hospital coding and statistics.25 In systems where payment to the healthcare service is reliant 123 
on coding data, external factors such as reimbursement incentives or local practice variations 124 
can cause bias.26 In large international trials, a further concern is the heterogeneity and 125 
reporting biases of different healthcare systems. Despite this, routinely collected hospital 126 
admission statistics have been used to conduct research for many years. Guidelines have 127 
helped to standardise definitions for trialists and registries.27 This has led to the delivery of 128 
randomised controlled trials, and is gaining popularity.  129 
 130 
A systematic review in 2001 found accuracy was high in the United Kingdom, especially in 131 
diagnostic codes.28 In 2012, Burns et al conducted a further systematic review of 32 studies29 132 
and found that since 2002, the accuracy of hospital coding, particularly in primary diagnosis, 133 
had improved from 74 to 96%. Whilst there remains a degree of variability especially for 134 
surgical procedures, the current drive for healthcare quality improvement has also enhanced 135 
the accuracy of hospital coding further.30,31 The literature therefore suggests that routinely 136 
collected data are robust for use in research and clinical trials.29  137 
 8 
 138 
In the West of Scotland Coronary Prevention Study (WOSCOPS),32 independently adjudicated 139 
clinical endpoint data were compared with routinely collected electronic health record data. 140 
There was excellent agreement with 100% of deaths and >95% of non-fatal clinical events 141 
being identified through health record linkage. As a result, subsequent follow up for over 20 142 
years has now been performed entirely through routinely collected data.34,35 Similar findings 143 
have also been found in the more contemporary aspirin for primary prevention in persons 144 
with diabetes mellitus (ASCEND) trial, where hospital episode statistics in England were 145 
compared with adjudicated clinical endpoints and effect size estimates for the primary 146 
outcome were again very similar (personal communication, Jane Armitage, University of 147 
Oxford). 148 
 149 
Many trials are now using routinely collected health data for clinical endpoint assessments. 150 
The Scottish computed tomography (CT) of the heart (SCOT-HEART) trial36 aimed to establish 151 
the benefit of CT coronary angiography when implemented into routine clinical practice. The 152 
clinical endpoint of coronary heart disease death or non-fatal myocardial infarction was 153 
identified through routinely collected health records data. With the introduction of CT 154 
coronary angiography, the national healthcare system observed lower rates of myocardial 155 
infarction, and this is ultimately the most important outcome for the healthcare provider. If 156 
site investigator reporting or clinical endpoint adjudication had been used, it is highly likely 157 
that absolute numbers of events would have differed, but the overall effect size is unlikely to 158 
change. This use of national electronic health record data has the potential for being 159 
automated, relatively independent of site or trial investigators, and markedly efficient.37 160 
 161 
 9 
Routinely collected healthcare record data can also be used for endpoint adjudication if 162 
required. The High-Sensitivity Troponin in the Evaluation of patients with suspected Acute 163 
Coronary Syndrome (High-STEACS) trial compared outcomes in consecutive patients 164 
evaluated using two cardiac troponin tests to determine whether implementing a more 165 
sensitive test improved diagnosis and reduced subsequent attendance with myocardial 166 
infarction or cardiovascular death.38 All deaths and hospital attendances were adjudicated 167 
using linked routine healthcare data. Quick access and lower costs made this method an 168 
attractive alternative standard approach, although it would be limited to countries that have 169 
access to comprehensive and robust systems to capture data from electronic health records. 170 
 171 
In the United Kingdom, the National Cancer Intelligence Network combined data from eight 172 
cancer registries, the Office for National Statistics and the Hospital Episode Statistics to create 173 
the National Cancer Data Repository (NCDR).39 These data have again demonstrated very high 174 
levels of consistency with clinical trial data: concordance of 99% for treatment and 96% for 175 
outcomes including 100% for 30-day mortality and near identical survival at 5-years.40 176 
However, these approaches do require substantial upfront investment to standardise and to 177 
collate the data but once achieved, they are reliable and robust.41  178 
 179 
Conclusions 180 
Adjudication is an important tool, but like all tools, it is not appropriate for every situations 181 
(Table). There are important limitations which need to be considered when deciding whether 182 
to use it. The belief that a diagnosis made by endpoint adjudication is superior to the site 183 
investigator has never been substantiated. Indeed, the evidence suggests that treatment 184 
effect estimates rarely differ between site investigators and clinical endpoint committee. It is 185 
 10 
difficult to conclude that adjudication is a gold standard that should be applied to every study. 186 
The use of routinely collected healthcare data has several strengths including being generally 187 
independent, comprehensive and highly cost effective, as well as being truly reflective of the 188 
impact on the healthcare system within which the intervention is being assessed. Whilst 189 
scientifically this may be less robust, the approach is arguably more important and relevant 190 
for the health care system and society since this will be how a new healthcare intervention 191 
will be applied in the real world. This begs the question of whether such approaches should 192 
be the gold-standard when assessing the impact of implementing healthcare interventions in 193 
the real world.194 
 11 
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The platelet inhibition and patient outcomes (PLATO) trial5 took a novel 
approach to screen for unreported clinical endpoint events. In addition 
to data supplied by site investigators, the clinical endpoint committee 
had access to background biomarker analysis performed on serial 
samples taken from study participants. This background screening led 
to 101 more events being adjudicated as true myocardial infarctions 
than reported by the site investigators.4 Without such background 
screening, the true prevalence of events will almost always be 
underestimated and this further reduces the sensitivity of identifying 
potentially important clinical events. It is interesting to note that, whilst 
the point estimate of the treatment effect size remained unchanged 
whether this approach was incorporated or not, the confidence interval 
around the estimate was broader using site investigator reported 
events. Here the additional screening eliminated the reliance on site 
reporting and therefore led to a more statistically robust conclusion.4 
 
 




























A study looking at the effect of implantable gentamicin-collagen sponge 
on sternal wound infections had an adjudication panel that included 
three experts in infectious diseases who were blinded to the treatment 
assignment.9 Possible infections were identified by triggered events on 
an electronic case report form which led to a review of the entire 
medical records of 128 patient at considerable cost. The investigators 
presented the data from both the principal investigators’ and the 
adjudication panel, and found results were similar with no benefit in 
the gentamicin arm as compared to the control arm. 
 




























In the cangrelor versus standard therapy to achieve optimal management of platelet 
inhibition (CHAMPION PHOENIX) trial, the endpoint of myocardial infarction following 
percutaneous coronary intervention varied over 3-fold between the clinical endpoint 
committee and the site investigators.12 It is perhaps unsurprising that site investigators 
were more reluctant to attribute peri-procedural events as myocardial infarction. In 
cases where there may be bias, or a likelihood of poor interobserver reproducibility, 
adjudication helps to prevent high rates of misclassifications. Despite this, the primary 
endpoint findings remained valid and indeed the events identified by the site 
investigators (also blind to treatment allocation) demonstrated the largest treatment 
effect size, perhaps underlining that they report the more clinically significant events. 
Although the number of endpoints can vary substantially, the ‘misclassification’ of 
events did not lead to a difference in study conclusions. 
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In the 5-year outcomes in the evaluation of drug-eluting stents versus coronary artery 
bypass surgery for left main revascularisation (EXCEL) trial, coronary stenting was 
reported as non-inferior to surgery.15 The trial endpoints were all adjudicated but there 
is controversy over the way in which myocardial infarction was defined and 
adjudicated. Unlike previous trials of left main stem revascularisation which found 
stenting to be inferior to surgery,16 the primary composite outcome of death, 
myocardial infarction or stroke in the EXCEL trial included periprocedural myocardial 
infarction. The definition of periprocedural myocardial infarction in EXCEL differed 
from the Universal Definition,17 favoured the use of creatine kinase-MB over troponin, 
applied the same thresholds for surgery and stenting, and did not require ancillary 
evidence from coronary angiography or cardiac imaging.18 As a consequence, the 
endpoint committee identified an excess of procedural events of uncertain clinical 
significance in those undergoing surgery that was offset by an increase in spontaneous 
myocardial infarctions over time in those undergoing stenting.19 Given all-cause 
mortality was higher in patients undergoing stenting, and the secondary outcome of 
myocardial infarction defined by the Universal Definition criteria remains unreported, 
doubts remain as to whether these strategies are truly equivalent. Indeed, the 
European Association of Cardio-Thoracic Surgeons has since made the unprecedented 
decision to reverse its endorsement of the recommendations based on the EXCEL trial 
in the joint myocardial revascularisation guidelines. 
 
 
Clinical Trial Example 5 
 
 
 In the percutaneous closure of the left atrial appendage versus warfarin therapy 
for prevention of stroke in patients with atrial fibrillation (PROTECT-AF) trial, 
excessive bleeding was a key safety endpoint.21 Adjudication was independent 
but unblinded, and the authors reported a 90% reduction in rates of 
haemorrhagic stroke but this has been subsequently challenged.22 A Food and 
Drug Administration review found uneven adjudication of haemorrhagic stroke 
in the trial whereby falls with subsequent subdural haematomas were labelled 
as a positive event in the warfarin group (5 of the total 10), but not in the device 
group (3 in total). This led to an overestimate of safety benefit of the treatment 
intervention due to endpoint adjudication. 
 




- Improves specificity by 
consistently applying a 
standardised definition.4,5
- Limits ascertainment bias 
particularly in unblinded trials
Improved scientific acceptability 
of trial results
- Reliant on events reported by 
site investigators
- Data may be incomplete or 
inconsistent.21,22
- Substantial cost and effort. 10
- Inflexible application of 
endpoint diagnosis may lead to 
false conclusions
- Regulatory drug 
trials
- Endpoint is difficult 
to define
- Investigators or 
participants are 







- Decision based on full clinical 
context
- Improved sensitivity
- Potentially as effective at 
determining treatment effect
- May be subject to selection 
bias from both over and 
underreporting.
- Reduced specificity due to 
inconsistent application of 
endpoint diagnoses
- Endpoints are 
clearly defined and 
easily standardised










- Reflects impact of intervention 
on the healthcare system
- Ceding control of endpoint 
definitions gives added level of 
independence.
- Potential use with artificial 
intelligence and machine 
learning techniques.
- Reliant on comprehensive and 
robust data capture from 
healthcare information systems.
- Dependent on a stable 
population.
- Definitions of data collected 
may change during the study
- Assessment of 








Table. Methods of clinical endpoint ascertainment in clinical trials 
Clinical Case Example 1.
A participant in an investigator-led multicentre randomised
controlled trial (>1500 participants in >30 centres) dies in
hospital 3 days after being admitted with a fall at home.
Excellent hospital records are available to allow the clinical
endpoint committee to adjudicate the cause of death. The
patient has a background of aortic stenosis, coronary heart
disease, frailty, heart failure and a recent diagnosis of
breast cancer. On arrival in hospital, the patient has
evidence of widespread trauma including multiple fractured
ribs, bilateral haemo-thoraces, liver contusions and pelvic
fluid on CT scan. The ECG shows 1-2 mm of anterior ST
elevation and cardiac troponin is mildly elevated. There is
evidence of heart failure with marked oedema and lung
crepitations on auscultation. The patient is made not for
resuscitation and dies within 3 days of admission. The local
investigator certifies the death as due to 1 A) Heart failure,
1 B) acute coronary syndrome and 2) aortic stenosis. The
adjudication committee are equally split on the cause of
death as cardiovascular and non-cardiovascular. The local
investigators opinion is considered important by the
endpoint committee and the death is designated as
“cardiovascular” despite severe trauma being the apparent
direct cause of death.
Panel
Clinical Case Example 2.
A participant of a major respiratory,
pharma-sponsored, international,
multicentre randomised controlled trial
(>15,000 participants in over 1,200
centres in more than 40 countries) is
lost to follow up. A private detective is
hired to find the participant. The
detective attends the participants home
at a trailer park but cannot contact them.
A passer-by walking their dog shares
with the detective that the participant
had died. The circumstances of their
death are unknown, and the death was
not registered (not a legal requirement
in their place of residence). The
deceased participant had no savings
and was cremated by their fellow
residents with an impromptu pyre and
wake at the trailer park. The fatal
primary endpoint was therefore defined
by the testimony of the passer-by
walking his dog
